Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.

13 Jul 2011

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.

11 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

AMRI, Proteros ink new partnership

AMRI and Proteros Biostructures GmbH announced today that they have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallization and X-ray structural analysis, provides services that complement AMRI's existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.

28 Jun 2011

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed dosing the first patient in Part B of the ongoing Phase I study.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Flamel, Digna Biotech enter joint development agreement for multiple products

Flamel Technologies SA and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

27 Jun 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.

24 Jun 2011

MAP to present LEVADEX data on migraine at 15th Congress of IHC

MAP Pharmaceuticals, Inc. today announced that LEVADEX orally inhaled migraine drug will be featured in four poster presentations, including one late-breaker presentation, at the 15th Congress of the International Headache Society (IHC) in Berlin, Germany on June 23-26, 2011.

23 Jun 2011

PNAS publishes Roche manuscript on generation of human bispecific IgG antibodies

The Roche manuscript: "Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies" has been published in the prestigious Proceedings of the National Academy of Sciences of the USA.

23 Jun 2011

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase Ib clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus (HCV) infection.

22 Jun 2011

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.

21 Jun 2011

Concert earns $4M milestone payment from GSK collaboration

Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone in its strategic alliance with GlaxoSmithKline for its HIV protease inhibitor development program, resulting in a $4 million milestone payment to Concert.

20 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.

16 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

Positive results from Neurelis NRL-01 Phase 1 trial against epilepsy

Neurelis, Inc. today announced the results of a randomized crossover study in healthy volunteers assessing diazepam pharmacokinetics and bioavailability after administration of their proprietary intranasal diazepam formulations and intravenous injection.

15 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Pharmacokinetics News and Research

Further Reading

Arena reports APD811 Phase 1 trial results against pulmonary arterial hypertension

Sinapis completes first clinical trial of lead drug for stroke and traumatic brain injury

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

AMRI, Proteros ink new partnership

Nile completes dosing in Part B of cenderitide Phase I study for ADHF

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

Flamel, Digna Biotech enter joint development agreement for multiple products

Positive results from Stealth's Bendavia Phase I renal impairment study

PCIB reports main results of Amphinex Phase I/II study against multiple cancers

MAP to present LEVADEX data on migraine at 15th Congress of IHC

PNAS publishes Roche manuscript on generation of human bispecific IgG antibodies

Medivir initiates TMC649128 phase Ib trial in chronic hepatitis C

Halozyme to present three data on Ultrafast Insulin programs at ADA 2011

Concert earns $4M milestone payment from GSK collaboration

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Positive results from Neurelis NRL-01 Phase 1 trial against epilepsy

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Industry Focus - Biopharma eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News